NCT00011414View on ClinicalTrials.gov

Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric Patients With Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

February 15, 2001

Primary Completion Date

November 28, 2007

Study Completion Date

January 13, 2016

Conditions
Wilms' TumorSarcomaAdenaocortical CarcinomaRefractory CancerColdrhood Cancer
Interventions
DRUG

Tariquidar

IV alone for 1 dose (Day -1), then in combo for rest of cycle (Day 1, etc). Given in combo with one of the following: Doxorubicin (50 mg/m2 IV over 15 min on day 1), Vinorelbine (20 mg/m2 IV over 10 min on days 1 and 8), or Docetaxel (75 mg/m2 IV over 60 min on day 1).

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00011414 - Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric Patients With Solid Tumors | Biotech Hunter | Biotech Hunter